Total Payments
$2.2M
2024 Payments
$80,740
Companies
46
Transactions
1,862
Payment Breakdown by Category
Other$1.5M (71.3%)
Consulting$320,064 (14.8%)
Travel$175,417 (8.1%)
Food & Beverage$56,132 (2.6%)
Research$53,037 (2.5%)
Education$13,615 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $763,853 | 216 | 35.4% |
| Grant | $455,800 | 11 | 21.1% |
| Consulting Fee | $320,064 | 158 | 14.8% |
| Honoraria | $256,231 | 52 | 11.9% |
| Travel and Lodging | $175,417 | 515 | 8.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $62,080 | 15 | 2.9% |
| Food and Beverage | $56,132 | 827 | 2.6% |
| Unspecified | $53,037 | 50 | 2.5% |
| Education | $13,615 | 18 | 0.6% |
Payments by Type
General
$2.1M
1,812 transactions
Research
$53,037
50 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $638,028 | 253 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $323,973 | 267 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $187,012 | 212 | $0 (2024) |
| Celgene Corporation | $155,020 | 135 | $0 (2022) |
| Amgen Inc. | $154,721 | 131 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $105,347 | 118 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $87,405 | 89 | $0 (2024) |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $80,835 | 122 | $0 (2023) |
| UCB, Inc. | $70,197 | 110 | $0 (2024) |
| PFIZER INC. | $66,451 | 32 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $80,740 | 103 | PFIZER INC. ($55,536) |
| 2023 | $63,500 | 118 | Almirall LLC ($17,105) |
| 2022 | $490,808 | 209 | ABBVIE INC. ($302,903) |
| 2021 | $246,249 | 121 | AbbVie Inc. ($146,821) |
| 2020 | $138,933 | 136 | Amgen Inc. ($41,553) |
| 2019 | $904,839 | 887 | Sun Pharmaceutical Industries Inc. ($275,169) |
| 2018 | $225,757 | 265 | Novartis Pharmaceuticals Corporation ($65,080) |
| 2017 | $5,402 | 23 | Regeneron Pharmaceuticals, Inc. ($3,069) |
All Payment Transactions
1,862 individual payment records from CMS Open Payments — Page 1 of 75
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | Galderma Laboratories, L.P. | — | Travel and Lodging | In-kind items and services | $198.59 | General |
| 12/27/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $89.97 | General |
| 12/20/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $119.54 | General |
| Category: Immunology | ||||||
| 12/13/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $74.83 | General |
| Category: DERMATOLOGY | ||||||
| 11/22/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $75.54 | General |
| 11/15/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $30.26 | General |
| Category: Inflammation | ||||||
| 11/15/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: Dermatology | ||||||
| 11/14/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $120.79 | General |
| Category: DERMATOLOGY | ||||||
| 11/14/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $28.88 | General |
| Category: Immunology | ||||||
| 11/14/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $17.88 | General |
| 11/14/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $17.63 | General |
| 11/10/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $114.79 | General |
| Category: Immunology | ||||||
| 11/09/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | — | Food and Beverage | In-kind items and services | $109.79 | General |
| 11/08/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $135.00 | General |
| 11/08/2024 | Sandoz Inc. | — | Food and Beverage | In-kind items and services | $57.50 | General |
| 11/04/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $72.34 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/26/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $57.76 | General |
| Category: Dermatology | ||||||
| 10/25/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $110.12 | General |
| Category: Immunology | ||||||
| 10/25/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $80.78 | General |
| Category: Immunology | ||||||
| 10/25/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $57.70 | General |
| Category: IMMUNOLOGY | ||||||
| 10/25/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $48.46 | General |
| 10/25/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $13.15 | General |
| Category: Immunology | ||||||
| 10/18/2024 | PFIZER INC. | CIBINQO (Drug) | Food and Beverage | In-kind items and services | $104.58 | General |
| Category: Inflammation & Immunology | ||||||
| 09/23/2024 | Galderma Laboratories, L.P. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,400.00 | General |
| 09/20/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $94.70 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ABROCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $9,940 | 8 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >=6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $6,031 | 18 |
| OPTUM PSO Manuscript - Submission to Journal of Health Economics | Amgen Inc. | $5,732 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $5,597 | 3 |
| HEALTH ECONOMICS OUTCOME RESEARCH RELATED TO DUPIXENT | Regeneron Pharmaceuticals, Inc. | $3,000 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $3,000 | 1 |
| OPTUM PsA Manuscript - Submission to Advances in Therapy | Amgen Inc. | $2,866 | 1 |
| OPTUM VS2 PSO Manuscript - Journal of Comparative Effectiveness Research | Amgen Inc. | $2,866 | 1 |
| A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WITH A LONG TERM EXTENSION PERIOD | Eli Lilly and Company | $2,750 | 1 |
| AN OPEN-LABEL STUDY OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS DUPILUMAB CLINICAL TRIALS | Regeneron Pharmaceuticals, Inc. | $2,382 | 1 |
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $2,344 | 3 |
| AD Marketscan AD and CV events in US TRUVEN database | GENZYME CORPORATION | $1,250 | 1 |
| A Phase 4, Multicenter, Randomized, Placebo-controlled, Double-blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate Plaque Psoriasis (CC-10004-PSOR-012) | Celgene Corporation | $1,144 | 1 |
| The Use of Real-World Data to Evaluate the Association Between Atopic Dermatitis and Cardiovascular Disease: A Retrospective Claims Analysis | SANOFI-AVENTIS U.S. LLC | $821.40 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIA | UCB, Inc. | $820.00 | 2 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY WITH A 24-WEEK ACTIVE-CONTROLLED INITIAL TREATMENT PERIOD FOLLOWED BY A 32-WEEK, DOSE-BLIND MAINTENANCE TREATMENT PERIOD TO EVALUATE THE EFFICACY | UCB, Inc. | $820.00 | 2 |
| Eastman | Janssen Research & Development, LLC | $680.00 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONG-TERM SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $552.86 | 1 |
| CC-10004-PSOR-012 - A Phase 4, Multicenter, Randomized, Placebo-controlled, Double-blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate Plaque Psoriasis | Celgene Corporation | $442.00 | 1 |
About Dr. Jashin Wu, M.D
Dr. Jashin Wu, M.D is a Dermatology healthcare provider based in Corona, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1407953102.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jashin Wu, M.D has received a total of $2.2M in payments from pharmaceutical and medical device companies, with $80,740 received in 2024. These payments were reported across 1,862 transactions from 46 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($763,853).
Ad
Practice Information
- Specialty Dermatology
- Location Corona, CA
- Active Since 09/17/2006
- Last Updated 03/07/2025
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1407953102
Products in Payments
- SKYRIZI (Biological) $437,792
- ILUMYA (Biological) $290,056
- Otezla (Drug) $281,833
- COSENTYX (Biological) $185,951
- DUPIXENT (Biological) $70,107
- Humira (Biological) $59,816
- RINVOQ (Biological) $57,222
- Skyrizi (Biological) $55,165
- SILIQ (Drug) $52,710
- DUPIXENT (Drug) $47,665
- Cimzia (Drug) $45,690
- ORENCIA (Biological) $38,441
- ILUMYA (tildrakizumab-asmn) injection (Biological) $23,420
- DUOBRII (Drug) $21,236
- TALTZ (Drug) $19,143
- ENSTILAR (Drug) $18,313
- Clarify Medical (Device) $17,875
- Klisyri (Drug) $17,238
- KLISYRI (Drug) $15,533
- Otezla (Biological) $14,330
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Corona
Babak Roshdieh, M.d, M.D
Dermatology — Payments: $8,831
Dermatology $8,831
Mr. Manouchehr Seyfzadeh, M.d., Ph.d, M.D., PH.D
Dermatology — Payments: $4,890
Dermatology $4,890
Dr. Anand Bhupathy, D.o, D.O
Dermatology — Payments: $3,444
Dermatology $3,444
Caroline Levanovic, Pa-C, PA-C
Dermatology
Dermatology